{"hands_on_practices": [{"introduction": "Understanding metabolic disorders often begins at the level of enzyme kinetics. This exercise applies the fundamental Michaelis-Menten model to UGT1A1, the key enzyme responsible for making bilirubin water-soluble for excretion. By calculating and comparing the conjugation rates for a wild-type versus a common variant genotype, you will gain a quantitative appreciation for how genetic variations can directly impact metabolic capacity, providing the molecular basis for conditions like Gilbert's syndrome [@problem_id:2569714].", "problem": "In hepatocytes, unconjugated bilirubin is detoxified by uridine 5'-diphospho-glucuronosyltransferase (UGT) isoform UGT1A1, which catalyzes the glucuronidation of bilirubin prior to biliary excretion. Consider the intracellular free bilirubin concentration to be $10\\,\\mu\\mathrm{M}$, with the co-substrate uridine 5'-diphosphoglucuronic acid saturating. Assume a single-substrate, steady-state enzymatic mechanism with saturation kinetics, where reducing the total active enzyme concentration scales the maximal velocity proportionally while leaving the substrate affinity unchanged. The wild-type enzyme exhibits a maximal velocity $V_{\\max,\\mathrm{WT}}=100\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}$ at a Michaelis constant $K_m=2\\,\\mu\\mathrm{M}$. In the homozygous UGT1A1*28/*28 genotype, the total active UGT1A1 abundance is reduced by $70\\%$ relative to wild-type, with no change in $K_m$.\n\nUsing these premises and first principles of steady-state enzyme kinetics, compute the bilirubin conjugation rates for wild-type and UGT1A1*28/*28 at $ [\\mathrm{bilirubin}]=10\\,\\mu\\mathrm{M}$. Provide your answer as two values ordered as $[\\text{wild-type},\\,\\text{UGT1A1*28/*28}]$. Express the rates in $\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}$ and round your final numerical results to four significant figures.", "solution": "The problem statement has been rigorously validated and is found to be scientifically grounded, self-contained, and well-posed. It presents a direct application of fundamental principles of steady-state enzyme kinetics to a biochemically relevant system. There are no logical inconsistencies, factual errors, or ambiguities. We shall therefore proceed with the derivation of the solution.\n\nThe rate of an enzyme-catalyzed reaction, under the assumption of a single substrate and steady-state conditions, is described by the Michaelis-Menten equation:\n$$\nv = \\frac{V_{\\max} [S]}{K_m + [S]}\n$$\nwhere $v$ is the reaction velocity, $V_{\\max}$ is the maximal velocity at saturating substrate concentration, $[S]$ is the substrate concentration, and $K_m$ is the Michaelis constant, which represents the substrate concentration at which the reaction velocity is half of $V_{\\max}$.\n\nThe problem provides the following parameters:\nSubstrate (bilirubin) concentration, $[S] = 10\\,\\mu\\mathrm{M}$.\nMichaelis constant, $K_m = 2\\,\\mu\\mathrm{M}$. This value is constant for both wild-type and the mutant genotype as it reflects substrate affinity, which is stated to be unchanged.\n\nFirst, we calculate the conjugation rate for the wild-type (WT) enzyme.\nFor the wild-type enzyme, the maximal velocity is given as $V_{\\max,\\mathrm{WT}} = 100\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}$.\nSubstituting the given values into the Michaelis-Menten equation:\n$$\nv_{\\mathrm{WT}} = \\frac{V_{\\max,\\mathrm{WT}} [S]}{K_m + [S]} = \\frac{(100\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}) \\times (10\\,\\mu\\mathrm{M})}{2\\,\\mu\\mathrm{M} + 10\\,\\mu\\mathrm{M}}\n$$\nWe can omit the units during the intermediate calculation as they are consistent.\n$$\nv_{\\mathrm{WT}} = \\frac{100 \\times 10}{2 + 10} = \\frac{1000}{12} = \\frac{250}{3}\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}\n$$\nAs a decimal, this is approximately $83.3333...\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}$.\n\nNext, we calculate the conjugation rate for the UGT1A1*28/*28 genotype.\nThe problem states that in this genotype, the total active enzyme abundance is reduced by $70\\%$ relative to wild-type. The maximal velocity, $V_{\\max}$, is directly proportional to the total enzyme concentration $[E_T]$ ($V_{\\max} = k_{cat}[E_T]$). Therefore, a reduction in enzyme abundance leads to a proportional reduction in $V_{\\max}$.\nThe new maximal velocity, $V_{\\max,*28}$, is:\n$$\nV_{\\max,*28} = V_{\\max,\\mathrm{WT}} \\times (1 - \\frac{70}{100}) = V_{\\max,\\mathrm{WT}} \\times 0.30\n$$\n$$\nV_{\\max,*28} = 100\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}} \\times 0.30 = 30\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}\n$$\nNow, we use this new $V_{\\max,*28}$ to calculate the reaction velocity for the UGT1A1*28/*28 genotype, noting that $[S]$ and $K_m$ are unchanged.\n$$\nv_{*28} = \\frac{V_{\\max,*28} [S]}{K_m + [S]} = \\frac{(30\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}) \\times (10\\,\\mu\\mathrm{M})}{2\\,\\mu\\mathrm{M} + 10\\,\\mu\\mathrm{M}}\n$$\n$$\nv_{*28} = \\frac{30 \\times 10}{2 + 10} = \\frac{300}{12} = 25\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}\n$$\nThe problem requires the final numerical results to be rounded to four significant figures.\nFor the wild-type rate:\n$$\nv_{\\mathrm{WT}} = 83.3333...\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}} \\approx 83.33\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}\n$$\nFor the UGT1A1*28/*28 rate:\n$$\nv_{*28} = 25\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}} = 25.00\\,\\mathrm{nmol\\,min^{-1}\\,mg^{-1}}\n$$\nThe two computed values, ordered as $[\\text{wild-type},\\,\\text{UGT1A1*28/*28}]$, are $83.33$ and $25.00$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n83.33 & 25.00\n\\end{pmatrix}\n}\n$$", "id": "2569714"}, {"introduction": "Building upon the concept of enzymatic capacity, this problem scales up to the physiological level to assess the balance between bilirubin production and clearance. You will model a scenario of severe hemolysis, a common cause of pre-hepatic jaundice, and calculate the daily load of bilirubin presented to the liver. This practice will sharpen your ability to use simple mass-balance calculations to predict the metabolic consequences of pathological states and understand why the liver's conjugation capacity can be overwhelmed [@problem_id:2569761].", "problem": "A patient with severe intravascular hemolysis releases hemoglobin into the reticuloendothelial system at a rate of $20\\,\\mathrm{g}$ hemoglobin per day. In heme catabolism, each heme is converted to biliverdin and then to bilirubin; for practical clinical estimation, assume an empirically established conversion factor whereby $1\\,\\mathrm{g}$ hemoglobin yields $35\\,\\mathrm{mg}$ bilirubin. The liver conjugates bilirubin via uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1), with a normal daily conjugation capacity of $300\\,\\mathrm{mg}$ bilirubin per day in this individual.\n\nUsing conservation of mass and the stated empirical yield, compute the fold-excess of bilirubin production over hepatic conjugation capacity, defined as the unitless ratio $R$ of daily bilirubin production to daily conjugation capacity. Report $R$ as a unitless number rounded to three significant figures. Do not include any units in your final answer.", "solution": "The problem requires the calculation of a unitless ratio, $R$, representing the fold-excess of daily bilirubin production over the liver's daily conjugation capacity. The problem statement will first be validated for its scientific and logical integrity.\n\nProblem Validation:\nStep 1: Extracted Givens.\n- Rate of hemoglobin release into the reticuloendothelial system: $20\\,\\mathrm{g}$ per day.\n- Empirical conversion factor: $1\\,\\mathrm{g}$ of hemoglobin yields $35\\,\\mathrm{mg}$ of bilirubin.\n- Daily hepatic conjugation capacity of bilirubin (by UGT1A1): $300\\,\\mathrm{mg}$ per day.\n- Definition of the ratio $R$: $R = \\frac{\\text{Daily bilirubin production}}{\\text{Daily conjugation capacity}}$.\n- Required format for the final answer: A unitless number rounded to three significant figures.\n\nStep 2: Validation of Givens.\nThe problem is scientifically grounded. The process described, heme catabolism, is a fundamental biochemical pathway. The values provided are consistent with a state of severe intravascular hemolysis. A daily turnover of $20\\,\\mathrm{g}$ of hemoglobin is pathologically high but physiologically possible. The empirical conversion factor of $35\\,\\mathrm{mg}$ of bilirubin from $1\\,\\mathrm{g}$ of hemoglobin is a standard clinical approximation, closely matching the theoretical stoichiometric yield. A hepatic conjugation capacity of $300\\,\\mathrm{mg}$ per day is within the normal range for an adult. The problem is well-posed, containing all necessary information for a unique solution, and is free of contradictions, ambiguities, or subjective claims. It is a formalizable problem in quantitative biochemistry.\n\nVerdict: The problem is valid. A solution will be derived.\n\nSolution Derivation:\nThe problem is a direct application of the principle of conservation of mass, using the provided conversion factors and rates. Let the daily rate of hemoglobin release be denoted by $\\dot{m}_{Hb}$, the empirical conversion factor by $\\eta$, the daily bilirubin production by $\\dot{m}_{bili,prod}$, and the daily hepatic conjugation capacity by $\\dot{m}_{bili,conj}$.\n\nThe givens are:\n$\\dot{m}_{Hb} = 20\\,\\mathrm{g/day}$\n$\\eta = \\frac{35\\,\\mathrm{mg\\,bilirubin}}{1\\,\\mathrm{g\\,hemoglobin}}$\n$\\dot{m}_{bili,conj} = 300\\,\\mathrm{mg/day}$\n\nFirst, we must calculate the total mass of bilirubin produced per day, $\\dot{m}_{bili,prod}$. This is found by multiplying the rate of hemoglobin release by the conversion factor $\\eta$.\n$$\n\\dot{m}_{bili,prod} = \\dot{m}_{Hb} \\times \\eta\n$$\nSubstituting the given values:\n$$\n\\dot{m}_{bili,prod} = (20\\,\\mathrm{g\\,Hb/day}) \\times \\left(\\frac{35\\,\\mathrm{mg\\,bilirubin}}{1\\,\\mathrm{g\\,Hb}}\\right)\n$$\nThe units of grams of hemoglobin ($\\mathrm{g\\,Hb}$) cancel, yielding the production rate of bilirubin in milligrams per day.\n$$\n\\dot{m}_{bili,prod} = 20 \\times 35\\,\\mathrm{mg/day} = 700\\,\\mathrm{mg/day}\n$$\nNext, we are asked to compute the ratio $R$, defined as the daily bilirubin production divided by the daily hepatic conjugation capacity.\n$$\nR = \\frac{\\dot{m}_{bili,prod}}{\\dot{m}_{bili,conj}}\n$$\nSubstituting the calculated production rate and the given conjugation capacity:\n$$\nR = \\frac{700\\,\\mathrm{mg/day}}{300\\,\\mathrm{mg/day}}\n$$\nThe units of milligrams per day ($\\mathrm{mg/day}$) cancel, resulting in a dimensionless (unitless) ratio, as required.\n$$\nR = \\frac{700}{300} = \\frac{7}{3}\n$$\nThe problem requires the final answer to be rounded to three significant figures. We perform the division:\n$$\nR = 2.3333\\ldots\n$$\nRounding to three significant figures gives:\n$$\nR \\approx 2.33\n$$\nThis value represents that the patient's bilirubin production rate is $2.33$ times the liver's capacity to conjugate it, which would lead to a rapid accumulation of unconjugated bilirubin and subsequent jaundice.", "answer": "$$\n\\boxed{2.33}\n$$", "id": "2569761"}, {"introduction": "We now pivot from heme catabolism to the intricate pathway of heme synthesis and its associated disorders, the porphyrias. This diagnostic challenge simulates a complex clinical case, requiring you to act as a biochemical detective. By systematically analyzing a patient's symptoms and a suite of laboratory data—from urinary precursors to fecal porphyrin profiles and plasma fluorescence—you will practice the critical reasoning needed to integrate disparate evidence and pinpoint a specific enzymatic defect within the heme biosynthetic pathway [@problem_id:2569712].", "problem": "A $34$-year-old individual presents with recurrent episodes of severe abdominal pain, tachycardia, and transient hypertension that resolve over several days, as well as a long-standing history of photosensitivity manifesting as blistering lesions on sun-exposed skin. During an acute episode, biochemical testing shows urine delta-aminolevulinic acid (ALA) $18$ mg/g creatinine (reference $<4$) and porphobilinogen (PBG) $12$ mg/g creatinine (reference $<2$). Urinary porphyrin fractionation reveals only modest increases in total porphyrins with no predominance of highly carboxylated species. Red blood cell (RBC) free protoporphyrin is $40$ $\\mu$g/dL RBC (reference $<80$). Fecal porphyrin fractionation demonstrates markedly elevated total porphyrins with protoporphyrin comprising approximately $70\\%$ of total and coproporphyrin III approximately $20\\%$ of total, yielding a protoporphyrin to coproporphyrin ratio of roughly $3.5:1$. Plasma fluorescence scanning after excitation at $405$ nm shows a single, sharp emission peak at $626$ nm.\n\nUsing only the following foundational principles, localize the enzymatic block within the heme biosynthetic pathway by selecting the most likely deficient enzyme:\n- Heme biosynthesis proceeds from glycine and succinyl-coenzyme A through delta-aminolevulinic acid to porphobilinogen and then through a series of tetrapyrrole intermediates to heme; distinct enzymes catalyze each step.\n- The polarity and number of carboxylate groups on porphyrins determine their compartmental distribution and excretion: highly carboxylated porphyrins are more water-soluble and appear predominantly in urine, whereas less carboxylated and nonpolar porphyrins (for example, protoporphyrin) are excreted mainly in bile and feces.\n- Acute hepatic porphyrias are characterized during attacks by increased ALA and PBG; erythropoietic porphyrias primarily feature sustained overproduction of porphyrins in bone marrow and characteristic increases in RBC porphyrins.\n- Plasma fluorescence emission maxima of circulating porphyrins can help distinguish specific porphyrias because different porphyrin species and their protein-binding states exhibit characteristic emission wavelengths.\n\nWhich enzyme is most likely deficient?\n\nA. Delta-aminolevulinic acid dehydratase (porphobilinogen synthase)\n\nB. Porphobilinogen deaminase (hydroxymethylbilane synthase)\n\nC. Uroporphyrinogen decarboxylase\n\nD. Coproporphyrinogen oxidase\n\nE. Protoporphyrinogen oxidase\n\nF. Ferrochelatase", "solution": "The problem statement will first be validated for scientific and logical integrity.\n\n### Step 1: Extract Givens\nThe provided information is as follows:\n- **Patient Profile**: A `$34$`-year-old individual.\n- **Clinical Presentation**: Recurrent episodes of severe abdominal pain, tachycardia, and transient hypertension. Long-standing history of photosensitivity with blistering lesions on sun-exposed skin.\n- **Biochemical Data (Acute Episode)**:\n    - Urine delta-aminolevulinic acid (ALA): `$18$` mg/g creatinine (reference `$<4$`).\n    - Urine porphobilinogen (PBG): `$12$` mg/g creatinine (reference `$<2$`).\n    - Urinary porphyrin fractionation: Modest increases in total porphyrins, no predominance of highly carboxylated species.\n    - Red blood cell (RBC) free protoporphyrin: `$40$` $\\mu$g/dL RBC (reference `$<80$`).\n    - Fecal porphyrin fractionation: Markedly elevated total porphyrins. Protoporphyrin comprises approximately `$70\\%$` of total. Coproporphyrin III comprises approximately `$20\\%$` of total. The protoporphyrin to coproporphyrin ratio is approximately `$3.5:1$`.\n    - Plasma fluorescence scan: Excitation at `$405$` nm results in a single, sharp emission peak at `$626$` nm.\n- **Foundational Principles**:\n    1.  Heme biosynthesis pathway: glycine and succinyl-coenzyme A $\\rightarrow$ ALA $\\rightarrow$ PBG $\\rightarrow$ tetrapyrrole intermediates $\\rightarrow$ heme. Each step is catalyzed by a distinct enzyme.\n    2.  Porphyrin excretion: Highly carboxylated porphyrins are water-soluble and excreted in urine. Less carboxylated/nonpolar porphyrins (e.g., protoporphyrin) are excreted in bile and feces.\n    3.  Porphyria classification: Acute hepatic porphyrias show increased ALA and PBG during attacks. Erythropoietic porphyrias show sustained overproduction of porphyrins in bone marrow and increased RBC porphyrins.\n    4.  Plasma fluorescence: Different porphyrins have characteristic emission wavelengths.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is assessed against the required criteria.\n- **Scientifically Grounded**: The problem presents a classic clinical vignette of a specific type of porphyria. The heme synthesis pathway, the described symptoms (neurovisceral and cutaneous), and the biochemical markers (ALA, PBG, fecal porphyrins, plasma fluorescence) are all established concepts in biochemistry and clinical medicine. The data provided are consistent with a known inherited metabolic disorder. The problem is scientifically sound.\n- **Well-Posed**: The question asks for the localization of an enzymatic defect based on a set of clinical and laboratory data. The provided data is sufficient and specific enough to allow for a logical deduction leading to a unique answer among the common porphyrias. The problem is well-posed.\n- **Objective**: The description is factual and quantitative, presenting clinical observations and laboratory results without subjective or ambiguous language. It is objective.\n- **Completeness and Consistency**: The data set is comprehensive, including markers for acute attacks (ALA, PBG), porphyrin excretion patterns (urine vs. feces), erythropoietic involvement (RBC protoporphyrin), and a specific confirmatory test (plasma fluorescence). The data are internally consistent and point cohesively toward a single diagnosis. For example, the elevated ALA and PBG are consistent with the neurovisceral symptoms, and the fecal porphyrin profile is consistent with the photosensitivity and a specific downstream enzyme block.\n\n### Step 3: Verdict and Action\nThe problem is scientifically valid, well-posed, objective, and internally consistent. A solution can be derived from the provided information and principles.\n\n### Derivation of Solution\nThe objective is to identify the deficient enzyme in the heme biosynthetic pathway. We will use the provided principles to interpret the clinical and biochemical data.\n\n1.  **Classification of the Porphyria**: According to Principle 3, acute hepatic porphyrias are characterized by increased ALA and PBG during attacks. The patient's urine ALA (`$18$` mg/g) and PBG (`$12$` mg/g) are markedly elevated above the reference ranges. This confirms the presence of an acute hepatic porphyria, which explains the neurovisceral symptoms (abdominal pain, tachycardia, hypertension). The enzyme defect must therefore be located downstream of PBG synthesis, which causes accumulation of these precursors due to the loss of feedback inhibition on ALA synthase, the rate-limiting enzyme of the pathway.\n\n2.  **Evaluation of Symptoms**: The patient exhibits both acute neurovisceral symptoms and chronic cutaneous photosensitivity. This combination of symptoms is characteristic of two of the acute hepatic porphyrias: Hereditary Coproporphyria (HCP) and Variegate Porphyria (VP). Acute Intermittent Porphyria (AIP) is excluded because it typically does not cause photosensitivity.\n\n3.  **Analysis of Porphyrin Excretion**: Principle 2 states that less carboxylated porphyrins like protoporphyrin are excreted in feces. The patient has markedly elevated fecal porphyrins, with protoporphyrin being the predominant species (`$70\\%`), followed by coproporphyrin III (`$20\\%`). This points to the accumulation of the immediate precursors to protoporphyrin IX and coproporphyrin III, which are protoporphyrinogen IX and coproporphyrinogen III respectively. The pathway is as follows:\n    Uroporphyrinogen III $\\xrightarrow{\\text{Uroporphyrinogen Decarboxylase}}$ Coproporphyrinogen III $\\xrightarrow{\\text{Coproporphyrinogen Oxidase}}$ Protoporphyrinogen IX $\\xrightarrow{\\text{Protoporphyrinogen Oxidase}}$ Protoporphyrin IX $\\xrightarrow{\\text{Ferrochelatase}}$ Heme.\n\n    A defect in Coproporphyrinogen Oxidase (causing HCP) would lead to a massive accumulation of its substrate, coproporphyrinogen III, resulting in fecal excretion dominated by coproporphyrin III. A defect in Protoporphyrinogen Oxidase (causing VP) would lead to accumulation of its substrate, protoporphyrinogen IX, which is auto-oxidized to protoporphyrin IX for excretion. The patient's fecal profile, with a protoporphyrin to coproporphyrin ratio of `$3.5:1$`, strongly favors a block at Protoporphyrinogen Oxidase.\n\n4.  **Analysis of RBC and Plasma Data**: Principle 3 states that erythropoietic porphyrias feature increased RBC porphyrins. The patient's RBC free protoporphyrin is normal (`$40$` $\\mu$g/dL), which argues against a primary erythropoietic disorder like Erythropoietic Protoporphyria (EPP), which is caused by ferrochelatase deficiency. Furthermore, Principle 4 notes the diagnostic utility of plasma fluorescence. The finding of a single, sharp emission peak at `$626$` nm upon excitation at `$405$` nm is pathognomonic for Variegate Porphyria. This is due to the presence of a unique porphyrin-peptide complex in the plasma of VP patients.\n\n5.  **Conclusion**: The combination of neurovisceral attacks, cutaneous photosensitivity, elevated urinary ALA and PBG, a fecal porphyrin profile dominated by protoporphyrin, normal RBC protoporphyrin, and a plasma fluorescence emission peak at `$626$` nm is collectively diagnostic of Variegate Porphyria. The enzymatic defect in Variegate Porphyria is a deficiency of Protoporphyrinogen Oxidase.\n\n### Evaluation of Options\n\n**A. Delta-aminolevulinic acid dehydratase (porphobilinogen synthase)**: Incorrect. A deficiency in this enzyme would cause accumulation of ALA only. The patient has markedly elevated PBG, which is synthesized from ALA by this enzyme.\n\n**B. Porphobilinogen deaminase (hydroxymethylbilane synthase)**: Incorrect. Deficiency of this enzyme causes Acute Intermittent Porphyria (AIP). While AIP explains the elevated ALA and PBG and the neurovisceral symptoms, it does not typically cause the blistering photosensitivity seen in this patient.\n\n**C. Uroporphyrinogen decarboxylase**: Incorrect. Deficiency of this enzyme causes Porphyria Cutanea Tarda (PCT). PCT is characterized by photosensitivity, but it is not an acute hepatic porphyria and is not associated with elevated urinary ALA or PBG, nor with acute neurovisceral attacks. The primary biochemical finding in PCT is elevated urinary uroporphyrin, which was not observed.\n\n**D. Coproporphyrinogen oxidase**: Incorrect. Deficiency of this enzyme causes Hereditary Coproporphyria (HCP). While HCP can present with a mixed clinical picture similar to the patient's, the characteristic biochemical finding is a massive elevation of coproporphyrin III in feces and urine. The patient's fecal profile is dominated by protoporphyrin, not coproporphyrin.\n\n**E. Protoporphyrinogen oxidase**: Correct. Deficiency of this enzyme causes Variegate Porphyria (VP). This diagnosis perfectly aligns with all the provided data: the dual neurovisceral and cutaneous symptoms, elevated ALA and PBG, a fecal profile dominated by protoporphyrin, and the pathognomonic plasma fluorescence peak at `$626$` nm.\n\n**F. Ferrochelatase**: Incorrect. Deficiency of this enzyme causes Erythropoietic Protoporphyria (EPP). EPP is characterized by photosensitivity due to protoporphyrin accumulation, but it does not cause acute neurovisceral attacks and is not associated with elevated ALA or PBG. A key diagnostic feature of EPP is a marked elevation of RBC free protoporphyrin, which is normal in this patient.", "answer": "$$\\boxed{E}$$", "id": "2569712"}]}